DPP-4 Inhibitor Modulation of Dietary Preference and Caloric Intake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The Western world lifestyle, characterized by excessive intake of high-caloric, unhealthy foods rich in fat and carbohydrates, leads to obesity and related metabolic disorders, necessitating effective pharmaceutical interventions for weight management and dietary regulation.
Innovation Solution
The use of DPP-4 inhibitors, such as linagliptin, optionally combined with GLP-1 receptor agonists like exenatide, to reduce the intake of high-caloric foods and shift dietary preferences towards healthier options by modifying appetite and taste preferences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If DPP-4 inhibitors are used to reduce food intake and shift dietary preferences, then caloric intake and body weight decrease, but the complexity of pharmaceutical intervention increases
Solution Approach 1:
The invention changes the physiological parameters by using DPP-4 inhibitors to increase endogenous GLP-1 levels, which then modifies food preferences and reduces caloric intake. This approach addresses the contradiction by using a pharmacological parameter change (enzyme inhibition) to achieve the desired reduction in caloric intake without requiring complex behavioral or surgical interventions
2Weight of stationary object
If DPP-4 inhibitors combined with GLP-1 receptor agonists are used for weight management, then body weight and fat mass reduction is achieved, but the treatment complexity and potential side effects increase
Solution Approach 1:
The invention merges two pharmacological mechanisms (DPP-4 inhibition and GLP-1 receptor agonism) into a coordinated treatment approach. By combining these agents, the patent achieves enhanced weight and fat mass reduction through synergistic action on appetite regulation and energy metabolism, while the combination therapy allows for optimized dosing and potentially reduced side effects compared to higher doses of single agents
3Productivity
If conventional weight management methods (diet, exercise, behavioral modification) are used, then lifestyle improvement is achieved, but the time required and effort needed are significant
Solution Approach 1:
The invention applies preliminary action by using pharmacological intervention to pre-establish the physiological conditions necessary for weight loss before lifestyle modifications are fully implemented. The DPP-4 inhibitor and GLP-1 receptor agonist prepare the metabolic and appetite regulation systems in advance, making subsequent dietary and exercise interventions more effective and requiring less time to achieve meaningful weight loss results
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively decreases body weight, fat mass, and caloric intake, while promoting a healthier dietary balance, thereby addressing obesity and metabolic disorders like type 2 diabetes.
Implementation Method 1
The present invention relates to the use of a certain DPP-4 inhibitor (preferably linagliptin) to specifically modify and/or reduce the intake of food by a subject
Implementation Method 2
optionally in combination with one or more other active agents, such as e.g. including a GLP-1 receptor agonist, particularly a short acting GLP-1, GLP-1 mimetic or GLP-1 analogue, such as exenatide or native GLP-1
Data Source
AI summary
The present invention relates to the use of a certain DPP-4 inhibitor for modifying food intake and regulating food preference.